NCT05866783 Serum Glycomics as Prognostic and Diagnostic Biomarkers of Disease Recurrence in Liver Transplant Recipients With Hepatocellular Carcinoma
| NCT ID | NCT05866783 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Ghent |
| Condition | Prognostic Biomarker |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-04-28 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-04-28 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Liver transplantation (LT) is the only curative option for a selection of patients with hepatocellular carcinoma (HCC) based on clinical selection criteria known as the Milan criteria. Nevertheless, 15% of these patients still show tumour recurrence after LT. In a monocentric pilot study, we have demonstrated that specific changes in N-glycan profiles (measured before LT) occur in HCC patients receiving LT1. These specific changes proved to be strongly associated with the risk of HCC recurrence and overall death after LT, independent of the criteria used for stringent patient selection. Pathophysiologically, it is known that abberations in protein glycosylation are involved in the onset en development of HCC. As such, a prognostic biomarker was developed that can clearly differentiate between patients with and without increased risk of HCC recurrence. The primary goal of this research study is to set up a prospective, multicentre study in order to validate the prognostic value of this glycomics-based serum biomarker. As such, the risk of tumour recurrence in patients undergoing LT for HCC will be estimated independent from the Milan criteria and the French alpha-fetoprotein model as the current standard. The secondary goal is to explore the potential of serum glycomics as markers of early recurrence after LT for HCC. More specifically, we aim to investigate whether serial glycomics determination at fixed time points after LT could allow early detection of recurrent HCC even before it is visible on conventional imaging. Consequently, a diagnostic biomarker for monitoring early recurrence after LT could be developed with the potential of redirecting treatment strategies already in an early disease stage. In case the promising data from the pilot study will be confirmed, the prognostic biomarker could be implemented in daily clinical practice leading to optimization of patient selection using a simple blood test before LT. More specifically, this marker could improve organ allocation thus preventing unnessecary treatment toxicity for the patient and reducing the costs of treatment for society. Moreover, it should be emphasized that a patent application was already submitted and accepted in collaboration with TechTranfer of Ghent University (PCT/EP2021/057788-Prognostic markers of disease recurrence in liver transplant recipients with hepatocellular carcinoma).
Eligibility Criteria
Inclusion Criteria: * Signed and dated patient informed consent document * Diagnosis of hepatocellular carcinoma * Age ≥ 18 years * Ability to comply with protocol-specified evaluations and scheduled visits * Eligible for liver transplantation and/or active on the waiting list for liver transplantation * Consulted the department of Gastroenterology and Hepatology Exclusion Criteria: * Diagnosis of other liver tumors (eg. liver metastasis, cholangiocarcinoma)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05866783 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Prognostic Biomarker. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05866783 currently recruiting?
Yes, NCT05866783 is actively recruiting participants. Contact the research team at xavier.verhelst@uzgent.be for enrollment information.
Where is the NCT05866783 trial being conducted?
This trial is being conducted at Ghent, Belgium.
Who is sponsoring the NCT05866783 clinical trial?
NCT05866783 is sponsored by University Hospital, Ghent. The trial plans to enroll 500 participants.